RecruitingNCT04208828

IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy


Sponsor

University of Louisville

Enrollment

400 participants

Start Date

Jan 2, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.


Eligibility

Min Age: 12 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with gastrointestinal motility disorder, gastroparesis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

University of Louisville

Louisville, Kentucky, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04208828


Related Trials